Metoclopramide Accord

Metoclopramide Hydrochloride, the active ingredient in Metoclopramide Accord, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It treats nausea and vomiting, gastroparesis, gastro‑oesophageal reflux disease and migraine‑associated nausea in adult patients. GNH USA supplies Metoclopramide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide Accord acts on dopamine pathways and gastrointestinal motility to relieve several conditions.

Nausea and vomiting: reduces frequency and severity of episodes in postoperative, chemotherapy‑induced and other causes. Gastroparesis: accelerates gastric emptying and improves related symptoms. Gastro‑oesophageal reflux disease (GERD): enhances lower‑esophageal sphincter tone and gastric clearance. Migraine‑associated nausea: alleviates nausea accompanying migraine attacks.

Common Side Effects: - Drowsiness or fatigue - Restlessness or anxiety - Diarrhea or abdominal cramping - Dry mouth - Headache - Dizziness

Serious or Rare Side Effects: - Extrapyramidal reactions such as dystonia, akathisia, or parkinsonism - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic reactions

Precautions should be observed before initiating therapy.

Assess for history of movement disorders: avoid or use with caution in patients with Parkinson's disease or prior extrapyramidal reactions. Monitor for depression or suicidal thoughts: discontinue if severe mood changes occur. Use with caution in renal impairment: dose adjustment may be required. Avoid concomitant use with other dopamine antagonists: increased risk of additive side effects. Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Metoclopramide may interact with several medicines.

Major Interactions (Avoid): - Anticholinergic agents: may increase risk of extrapyramidal symptoms. - CYP2D6 inhibitors (e.g., fluoxetine): can raise plasma concentrations. - Other dopamine antagonists (e.g., phenothiazines): additive central effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., alcohol, benzodiazepines): may enhance sedation. - Serotonergic agents (e.g., ondansetron): potential for serotonin syndrome. - Drugs affecting QT interval (e.g., quinidine): may increase cardiac risk.